We are live on ! Find out more
ROSG

Rosetta Genomics
ROSG

Delisted

ROSG was delisted on the 21st of May, 2018.

1 hedge funds and large institutions have $0 invested in Rosetta Genomics in 2018 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $19K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$19K

ROSG Hedge Fund Activity: Q3 2018 in Review

1 of the 4,393 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics (ROSG) for Q3 2018, worth a combined $0 — down 100% from $19K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ROSG and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, exiting entirely with an estimated $19K sold.

  • 1 institutional investor held Rosetta Genomics (ROSG) as of Q3 2018, down from 2 in Q2 2018.
  • Funds reported $0 of Rosetta Genomics stock for Q3 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Rosetta Genomics positions in Q3 2018 and 1 closed out, a net change of -1 holder.
  • The largest Rosetta Genomics seller in Q3 2018 was Sabby Management, an estimated $19K sold.

Based on aggregated 13F filings for Q3 2018.